B R Southwell1, J B Furness. 1. Department of Gastroenterology, Murdoch Children's Research Institute, Parkville, Victoria 3052, Australia. southwell@murdoch.rch.unimelb.edu.au
Abstract
BACKGROUND AND AIMS: Previous immunohistochemical studies failed to reveal neurokinin (NK)(1) tachykinin receptors on intestinal muscle, despite convincing pharmacologic data indicating their presence. This study aimed to apply optimal immunohistochemical methods to reveal the receptors. METHODS: NK(1)-receptor immunoreactivity was examined by confocal microscopy in tissue incubated with or without 10(-7) mol/L substance P (SP), 10(-7) mol/L SP plus 10(-6) mol/L NK(1) receptor antagonist (CP99994), or with fluorescent cyanine 3.18 (Cy3) SP. RESULTS: Without incubation, NK(1)-receptor immunoreactivity was strong on muscle of the rectum and distal colon and weak in proximal colon and small intestine. NK(1) receptor was located on the surface of muscle cells in all gut regions. Exposure to SP increased the intensity of immunoreactivity, and the receptor moved into the cytoplasm. Mobilization of the receptor by SP was blocked by the NK(1)-receptor antagonist CP99994. Cy3-SP was internalized by muscle cells and colocalized with the receptor. NK(1)-receptor immunoreactivity occurred on crypt epithelial cells in the small intestine and the base of glands in the proximal colon. CONCLUSIONS: The NK(1) receptor occurs on the external muscle throughout the small and large intestines. SP binds and triggers NK(1)-receptor aggregation and internalization in the muscle.
BACKGROUND AND AIMS: Previous immunohistochemical studies failed to reveal neurokinin (NK)(1) tachykinin receptors on intestinal muscle, despite convincing pharmacologic data indicating their presence. This study aimed to apply optimal immunohistochemical methods to reveal the receptors. METHODS:NK(1)-receptor immunoreactivity was examined by confocal microscopy in tissue incubated with or without 10(-7) mol/L substance P (SP), 10(-7) mol/L SP plus 10(-6) mol/L NK(1) receptor antagonist (CP99994), or with fluorescent cyanine 3.18 (Cy3) SP. RESULTS: Without incubation, NK(1)-receptor immunoreactivity was strong on muscle of the rectum and distal colon and weak in proximal colon and small intestine. NK(1) receptor was located on the surface of muscle cells in all gut regions. Exposure to SP increased the intensity of immunoreactivity, and the receptor moved into the cytoplasm. Mobilization of the receptor by SP was blocked by the NK(1)-receptor antagonist CP99994. Cy3-SP was internalized by muscle cells and colocalized with the receptor. NK(1)-receptor immunoreactivity occurred on crypt epithelial cells in the small intestine and the base of glands in the proximal colon. CONCLUSIONS: The NK(1) receptor occurs on the external muscle throughout the small and large intestines. SP binds and triggers NK(1)-receptor aggregation and internalization in the muscle.
Authors: Douglas J Turner; Paul C Martin; Jaladanki N Rao; Jose Greenspon; Tongtong Zou; Barbara L Bass; Jian-Ying Wang; Eric D Strauch Journal: Ann Surg Date: 2007-03 Impact factor: 12.969
Authors: Yee Ian Yik; Pamela J Farmer; Sebastian K King; C W Chow; John M Hutson; Bridget R Southwell Journal: Pediatr Surg Int Date: 2011-02-02 Impact factor: 1.827
Authors: Marta Sofía Valero; Diego Santos Fagundes; Laura Grasa; María Pilar Arruebo; Miguel Ángel Plaza; María Divina Murillo Journal: Acta Pharmacol Sin Date: 2011-03-28 Impact factor: 6.150
Authors: Bernard T Drumm; Benjamin E Rembetski; Kaitlin Huynh; Aqeel Nizar; Salah A Baker; Kenton M Sanders Journal: FASEB J Date: 2020-06-15 Impact factor: 5.191